Publications:452
Accepting New Patients
Mount Sinai DoctorsTreats Children
Accepting New PatientsMarla C Dubinsky, MD
Pediatrics, Pediatric Gastroenterology
Book an Appointment
About Me
Dr. Dubinsky received her medical degree from Queen’s University, Canada. She completed her Pediatric Residency at Alberta Children’s Hospital, Calgary, Canada and her Clinical Fellowship in Gastroenterology and Nutrition at Sainte-Justine Hospital at the University of Montreal, Canada. She then completed her Research Fellowship in Inflammatory Bowel Disease at Cedars-Sinai Medical Center in Los Angeles where she then served as the Director of the Pediatric Inflammatory Bowel Disease Center before coming to Mount Sinai as the Chief of the Division of Pediatric Gastroenterology at the Mount Sinai Kravis Children's Hospital. She is also the Co-Director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center at Mount Sinai. Her primary research focuses on the influence of genetics and immune responses on the variability in clinical presentations, treatment responses and prognosis of early-onset IBD. Her other interests include the impact of IBD on fertility and pregnancy. She has lectured widely both nationally and internationally and has published in over 340 peer reviewed journals including The New England Journal of Medicine, Lancet, Gastroenterology, The Journal of Pediatric Gastroenterology and Nutrition, Inflammatory Bowel Diseases, Journal of Crohn’s and Colitis, and the American Journal of Gastroenterology. She also currently sits on the editorial boards of several leading journals.
Mount Sinai Health System’s Marla C. Dubinsky, MD, and Laurie A. Keefer, PhD, are co-founders of Trellus Health, which has entered into an exclusive multi-year contract with Mount Sinai to commercialize a patent-pending GRITT-IBD™ resilience assessment and personalized integrated care pathways. Read about "The Science of Resilience Meets Technology" in the 2021 Mount Sinai Kravis Children's Hospital Pediatric Report.
Dr. Dubinsky received the 2022 Sherman Prize National Recognizing for Excellence in Inflammatory Bowel Disease. Learn More Here.
The state of Florida requires out-of-state professionals who are registered to provide telehealth services to display a hyperlink to the Florida Department of Health telehealth web page. This allows Florida patients who are receiving medical care by telehealth to confirm the provider’s licensure and Florida registration.
Language
Position
Hospital Affiliations
- Mount Sinai Beth Israel
- Mount Sinai Morningside
- Mount Sinai Brooklyn
- Mount Sinai Queens
- The Mount Sinai Hospital
- Mount Sinai West
Research Topics
Inflammatory Bowel Disease (IBD), Personalized Medicine, Pharmacogenomics
About Me
Dr. Dubinsky received her medical degree from Queen’s University, Canada. She completed her Pediatric Residency at Alberta Children’s Hospital, Calgary, Canada and her Clinical Fellowship in Gastroenterology and Nutrition at Sainte-Justine Hospital at the University of Montreal, Canada. She then completed her Research Fellowship in Inflammatory Bowel Disease at Cedars-Sinai Medical Center in Los Angeles where she then served as the Director of the Pediatric Inflammatory Bowel Disease Center before coming to Mount Sinai as the Chief of the Division of Pediatric Gastroenterology at the Mount Sinai Kravis Children's Hospital. She is also the Co-Director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center at Mount Sinai. Her primary research focuses on the influence of genetics and immune responses on the variability in clinical presentations, treatment responses and prognosis of early-onset IBD. Her other interests include the impact of IBD on fertility and pregnancy. She has lectured widely both nationally and internationally and has published in over 340 peer reviewed journals including The New England Journal of Medicine, Lancet, Gastroenterology, The Journal of Pediatric Gastroenterology and Nutrition, Inflammatory Bowel Diseases, Journal of Crohn’s and Colitis, and the American Journal of Gastroenterology. She also currently sits on the editorial boards of several leading journals.
Mount Sinai Health System’s Marla C. Dubinsky, MD, and Laurie A. Keefer, PhD, are co-founders of Trellus Health, which has entered into an exclusive multi-year contract with Mount Sinai to commercialize a patent-pending GRITT-IBD™ resilience assessment and personalized integrated care pathways. Read about "The Science of Resilience Meets Technology" in the 2021 Mount Sinai Kravis Children's Hospital Pediatric Report.
Dr. Dubinsky received the 2022 Sherman Prize National Recognizing for Excellence in Inflammatory Bowel Disease. Learn More Here.
The state of Florida requires out-of-state professionals who are registered to provide telehealth services to display a hyperlink to the Florida Department of Health telehealth web page. This allows Florida patients who are receiving medical care by telehealth to confirm the provider’s licensure and Florida registration.
Language
Position
Hospital Affiliations
- Mount Sinai Beth Israel
- Mount Sinai Morningside
- Mount Sinai Brooklyn
- Mount Sinai Queens
- The Mount Sinai Hospital
- Mount Sinai West
Research Topics
Inflammatory Bowel Disease (IBD), Personalized Medicine, Pharmacogenomics
Clinical Focus
- Colonoscopy
- Crohn's Disease
- Gastroenterology
- Inflammatory Bowel Disease
- Ulcerative Colitis
- Upper GI Endoscopy
Video
Education
MD, Royal College of Physicians
Residency, Pediatrics
Alberta Childrens Hospital
Fellowship, Pediatric Gastroenterology
CHU Sainte Justine
Certifications
American Board of Pediatrics
Awards
2022
Sherman Prize Recipient
2010
International Organization for the Study of Inflammatory Bowel Disease
2009
Abe and Claire Levine Chair in Pediatric Inflammatory Bowel Disease
2008
Lectureship Award, University of Calgary
2007
Corrine and Lenny Sands Clinical Investigator Award
Research
Dr. Dubinsky's research interests include:
- Microbiome and genetics
- Pharmacogenetics
- Pregnancy, preconception, and fertility
- Prognostic models
- Therapeutic drug monitoring
Locations
Insurance Information
Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.
Patients with Cigna Medicare Advantage or Humana Medicare Advantage insurance: Please read this important message before booking to find out if out-of-network costs may apply to your next visit.
- The Susan & Leonard Feinstein IBD Clinical Center, 17 East 102nd Street, 5th Floor East, New York, NY, 10029
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Publications
Selected Publications
- Tofacitinib in Pediatric Ulcerative Colitis: A Retrospective Multicenter Experience. Oren Ledder, Michael Dolinger, Marla C. Dubinsky, Ronen Stein, Srisindu Vellanki, Rachel Buckuk, Ayesha Fatima, David L. Suskind, Jarrad Scarlett, Dennis Röser, Dror S. Shouval, Gabriele Meyer, Zarela Molle Rios, Gemma Pujol-Muncunill, Anna Lozano, Kaija Leena Kolho, Pejman Rohani, Seamus Hussey, Tim De Mejj, Travis Ayers, Victor Manuel Navas-López, Dan Turner, Christos Tzivinikos. Inflammatory Bowel Diseases
- The Urgency Numeric Rating Scale: Psychometric Evaluation in Adults with Crohn’s Disease. Marla Dubinsky, Aisha Vadhariya, Sylvia Su, Xian Zhou, Frederick Durand, Claudine Clucas, Larissa Stassek, Ariane K. Kawata, Simon Travis. Advances in Therapy
- Ustekinumab Drug Clearance Is Better Associated with Disease Control than Serum Trough Concentrations in a Prospective Cohort of Inflammatory Bowel Disease †. Andres J. Yarur, Thierry Dervieux, Ryan Ungaro, Elizabeth A. Spencer, Alexandra Bruss, Lizbeth Nunez, Brandon Berens, Séverine Vermeire, Zhigang Wang, John C. Panetta, Erwin Dreesen, Marla C. Dubinsky. Pharmaceutics
Patient Experience Star Ratings and Comments
The Patient Experience Star Rating reflects our patients’ perception of how well their Mount Sinai provider communicated with them during an office visit. The Star Rating is based on patient responses to three questions on a patient experience survey, a standardized questionnaire sent to verified patients and distributed by a third party vendor, Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score.
Care Provider’s Explanation
Care Provider’s Concern
Likelihood to Recommend Care Provider
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Dubinsky during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Genentech, Inc.
- Merck & Co., Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Dubinsky during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Genentech, Inc.
- Merck & Co., Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.